Efficacy of upadacitinib vs dupilumab for moderate-to-severe atopic dermatitis: analysis of time spent in itch response state from the Heads Up study

被引：0
|
作者：
Blauvelt, Andrew [1 ]
de Bruin-Weller, Marjolein [2 ]
Kwatra, Shawn G. [3 ]
Gooderham, Melinda J. [4 ]
Kim, Brian [5 ,6 ,7 ,8 ]
Liu, Yingyi [9 ]
Chu, Alvina D. [9 ]
Ofori, Sarah [9 ]
Platt, Andrew [9 ]
Calimlim, Brian M. [9 ]
Silverberg, Jonathan, I [10 ]
机构：
[1] Oregon Med Res Ctr, Portland, OR USA
[2] Univ Med Ctr Utrecht, Dept Dermatol & Allergol, Utrecht, Netherlands
[3] Johns Hopkins Univ, Sch Med, Baltimore, MD USA
[4] Queens Univ, Kingston, ON, Canada
[5] Icahn Sch Med Mt Sinai, Kimberly & Eric J Waldman Dept Dermatol, New York, NY USA
[6] Icahn Sch Med Mt Sinai, Mark Lebwohl Ctr Neuroinflammat & Sensat, New York, NY USA
[7] Icahn Sch Med Mt Sinai, Precis Immunol Inst, New York, NY USA
[8] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY USA
[9] AbbVie Inc, N Chicago, IL USA
[10] George Washington Univ, Sch Med & Hlth Sci, Dept Dermatol, Washington, DC USA
来源：
BRITISH JOURNAL OF DERMATOLOGY | 2024年 / 190卷
关键词：
upadacitinib; dupilumab; atopic dermatitis; moderate-to-severe; pruritus;
D O I：
10.1093/bjd/ljad498.031
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
526
引用
收藏
页码：II28 / II29
页数：2
相关论文
共 50 条
  • [21] Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults
    Xu, Xinghua
    Zheng, Yi
    Zhang, Xin
    He, Yanling
    Li, Chengxin
    ONCOTARGET, 2017, 8 (65) : 108480 - 108491
  • [22] Efficacy and safety of dupilumab in adolescent patients with moderate-to-severe atopic dermatitis
    Cork, M. J.
    Eichenfield, L. F.
    Blauvelt, A.
    Rosmarin, D.
    Hussain, I.
    Davis, J. D.
    Li, M.
    Zhang, Q.
    Gadkari, A.
    Eckert, L.
    Kamal, M. A.
    Bansal, A.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (05) : S104 - S104
  • [23] Efficacy and tolerance of dupilumab in patients with moderate-to-severe atopic dermatitis and obesity
    Dupuis, Josephine
    Tauber, Marie
    Mahe, Emmanuel
    Jachiet, Marie
    Soria, Angele
    Tetart, Florence
    Puzenat, Eve
    Pasteur, Justine
    Raison-Peyron, Nadia
    Giordano-Labadie, Francoise
    Droitcourt, Catherine
    Leleu, Camille
    Nosbaum, Audrey
    Aubert, Helene
    Moigne, Marie L. E.
    Bernier, Claire
    Barbarot, Sebastien
    Ezzedine, Khaled
    Diaz, Emmanuelle
    Hubiche, Thomas
    Faiz, Sarah
    Azib, Selma
    Dezoteux, Frederic
    Chosidow, Olivier
    Staumont-Salle, Delphine
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2025, 39 (02) : e174 - e178
  • [24] Efficacy and safety of abrocitinib and upadacitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: A systematic review and meta-analysis
    Gao, Qin
    Zhao, Yanxia
    Zhang, Junling
    HELIYON, 2023, 9 (06)
  • [25] Efficacy and safety of switching from dupilumab to upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension trial
    Blauvelt, A.
    Ladizinski, B.
    Prajapati, V. H.
    Laquer, V.
    Fischer, A.
    Eisman, S.
    Wu, T.
    Vigna, N.
    Teixeira, H. D.
    Liu, J.
    Eyerich, K.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E142 - E142
  • [26] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    JAMA DERMATOLOGY, 2022,
  • [27] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    Teixeira, H. D.
    Simpson, E. L.
    JAMA DERMATOLOGY, 2024, 160 (03) : 370 - 370
  • [28] Efficacy and safety of upadacitinib in the treatment of moderate-to-severe atopic dermatitis: A systematic review
    Zhao, Dan-Jie
    Li, Xia
    Lin, Hai-Xia
    Zheng, Hong
    Zhou, Di
    Tang, Peng
    PLOS ONE, 2024, 19 (07):
  • [29] Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    JAMA DERMATOLOGY, 2022, 158 (02) : 219 - 219
  • [30] Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis: A Randomized Clinical Trial (vol 157, pg 1047, 2021)
    Blauvelt, A.
    JAMA DERMATOLOGY, 2024, 160 (09) : 1012 - 1012
12345